Active Pharmaceutical Ingredients
Tamsulosin HCl SR Pellets + Dutasteride Pellets are advanced multiparticulate systems designed for oral fixed-dose combination (FDC) therapies targeting Benign Prostatic Hyperplasia (BPH). This combination offers dual action: Tamsulosin provides immediate symptom relief through α1-blockade, while Dutasteride offers long-term management by reducing prostate size via 5α-reductase inhibition. The sustained-release profile ensures improved patient compliance and optimized therapeutic outcomes.
| Component | Function |
|---|---|
| Tamsulosin Hydrochloride | Active Pharmaceutical Ingredient (API) – SR agent |
| Dutasteride | Active Pharmaceutical Ingredient (API) – long-acting |
| Microcrystalline Cellulose (MCC) | Pellet core former / Binder |
| Lactose Monohydrate | Filler / Diluent |
| Hydroxypropyl Methylcellulose (HPMC) | Film-former and release modifier |
| Ethyl Cellulose (EC) | Sustained-release polymer (coating) |
| Dibutyl Sebacate | Plasticizer for coating flexibility |
| Talc | Anti-adherent in coating |
| Colloidal Silicon Dioxide | Glidant and anti-caking agent |
| Purified Water | Processing solvent (removed during drying) |
Salius Pharma offers Tamsulosin HCl SR + Dutasteride Pellets as a ready-to-formulate fixed-dose combination, manufactured in USFDA-approved, WHO-GMP, and ISO-certified facilities. Our pellets feature uniform drug distribution, excellent flow properties, and customizable release profiles. With a strong track record in regulated and semi-regulated markets, and robust regulatory support, Salius Pharma is your ideal partner for combination therapies targeting BPH.
We ensure prompt and reliable shipping worldwide. Delivery times may vary depending on destination, order volume, and regulatory requirements.
Looking to source Tamsulosin HCI SR Pellets + Dutasteride Pellets or other high-quality pharmaceutical pellet formulations?
Whether you need Active Pharmaceutical Ingredients (APIs), excipients, or regulatory support, our team is ready to provide reliable, compliant, and cost-effective solutions tailored to your market needs.
The contents of this page and any attachments are intended solely for the designated recipient(s) and may contain confidential and/or privileged information protected by law.
Any patented products are excluded from our offerings in regions where such patents are currently in force.
This combination delivers sustained-release Tamsulosin for symptom relief and Dutasteride for long-term disease management, offering comprehensive therapy for benign prostatic hyperplasia (BPH) with improved patient compliance.
The pellets use advanced coating technology to control the release of Tamsulosin while maintaining Dutasteride stability, ensuring consistent therapeutic levels over an extended duration.
Yes. The pellets are manufactured under GMP conditions and meet international quality and stability standards, making them suitable for export to regulated and semi-regulated markets.
Salius Pharma supplies CoA, MSDS, stability data, and export documentation, and packs the pellets in moisture-protected, export-grade containers to ensure product integrity during international transport.